Low T3 syndrome, often referred to as non-thyroidal illness syndrome (NTIS) or “sick euthyroid syndrome”, comprises a set of thyroid function test abnormalities observed during acute or chronic illnesses that do not primarily affect the thyroid, particularly in critical conditions and states of systemic inflammation. The most typical biochemical profile is a reduction in T3, both total and often free, with a non-elevated TSH, which may be normal or low, and normal or reduced T4 depending on the severity and duration of the illness. This is frequently associated with an increase in reverse T3 (rT3) due to remodelling of peripheral deiodination. Unlike primary hypothyroidism, in which the thyroid gland is diseased and TSH tends to increase, in low T3 syndrome the thyroid may be structurally intact, while the dynamic regulation of the hypothalamic-pituitary-thyroid axis and, above all, tissue thyroid hormone metabolism are altered.
The most clinically relevant point is that low T3 syndrome does not automatically represent a “thyroid disorder that must be corrected”, but rather an endocrine-metabolic phenotype of the diseased organism that integrates signals related to inflammation, stress, relative fasting, medications and remodelling of tissue thyroid hormone utilisation. The severity of these abnormalities often correlates with the severity of the underlying condition and with prognosis, but this association does not necessarily imply that thyroid hormone replacement provides a benefit in most clinical settings.
Low T3 syndrome is extremely common in hospital settings and represents one of the main causes of “abnormal thyroid function tests” in medical wards and, particularly, in intensive care units. Its frequency increases with the severity of the systemic illness. Mild forms may show an isolated reduction in T3, whereas more severe and prolonged conditions may also involve reduced T4 and a TSH that is more frequently low or inappropriately normal. In many studies involving critically ill populations, a large proportion of patients have a profile compatible with NTIS, and the extent of the T3 reduction, particularly when persistent, tends to be associated with adverse outcomes, length of hospital stay and mortality, reflecting the depth of systemic dysfunction.
The main risk factors correspond to conditions that generate an intense neuroendocrine and inflammatory response. In intensive care, sepsis, shock, acute respiratory failure, major trauma, burns, major surgery and multiple organ dysfunction syndromes are typical scenarios. In internal medicine, the syndrome is also observed in advanced heart failure, chronic kidney disease and dialysis, chronic liver disease, systemic inflammatory diseases, advanced malignancies and conditions of malnutrition or cachexia. A central element is the presence of an energy deficit or reduced substrate availability, which may be explicit, as in fasting or malnutrition, or functional, as in reduced intake combined with increased demand during physiological stress.
An important clinical role is played by medications and supportive therapies, which may contribute both to the development of the syndrome and to difficulties in its interpretation. Systemic glucocorticoids, dopamine and catecholamines, certain sedatives and analgesics, amiodarone, heparin due to analytical interference, iodinated contrast media and, more generally, medications that modify protein binding or peripheral conversion may alter TSH, T3 and T4, mimicking or amplifying the biochemical pattern. Pregnancy and the postpartum period, changes in binding proteins and alterations in hepatic and renal function also affect the interpretation of hormone measurements.
In clinical practice, low T3 syndrome should be considered particularly likely when thyroid function test abnormalities develop in association with a significant systemic illness, without a history suggesting pre-existing thyroid dysfunction and with a TSH that does not show the expected increase in the presence of low T4. In these settings, the pre-test probability of primary hypothyroidism is often lower than that of NTIS, requiring diagnostic reasoning centred on the patient rather than on laboratory results alone.
Low T3 syndrome does not have a single aetiology in the strict sense, because it represents the final expression of several mechanisms activated during systemic illness. The core pathogenetic process involves remodelling of thyroid hormone homeostasis at both central and peripheral levels. Under physiological conditions, the thyroid predominantly produces T4, which is converted into T3 within tissues by deiodinases, while the hypothalamic-pituitary-thyroid axis maintains a dynamic set point that integrates energy availability, temperature, stress and inflammation. In NTIS, this balance is “reprogrammed” by the diseased organism, affecting central secretion, transport, conversion and tissue availability.
During the acute phase of critical illness, an important component is the reduction in peripheral conversion of T4 into T3 and the increase in rT3 production. This occurs through changes in deiodinase expression and activity. Reduced type 1 deiodinase activity, together with increased type 3 deiodinase activity in various tissues, promotes a metabolic “shift” towards rT3 production and hormone inactivation. This remodelling is influenced by pro-inflammatory cytokines, oxidative stress, tissue hypoxia, perfusion abnormalities and changes in the intracellular environment. The result is a reduction in circulating T3, but the crucial point is that the relationship between serum concentrations and intracellular availability is not linear. Some organs may maintain relatively stable tissue levels through local compensatory mechanisms, whereas others may reduce thyroid hormone signalling as part of an energy-conservation metabolic programme.
At the central level, particularly in prolonged critical illness, a different pattern emerges, characterised by suppression of the axis at the hypothalamic and pituitary levels. Reduced hypothalamic TRH expression, associated with a TSH that is not appropriately elevated, contributes to reduced thyroid secretion and declining T4 levels. This phenotype may appear closer to functional central hypothyroidism, but it remains part of a stress physiology in which the organism does not simply “lose” thyroid function, but reallocates it in relation to nutrient availability, inflammation and survival requirements. In clinical practice, this distinction between the acute and prolonged phases helps explain why replacement with T4 or T3 may be biologically ineffective or potentially hazardous, and why some experimental approaches have investigated stimulation with hypothalamic releasing factors rather than simple peripheral hormone administration.
A further pathophysiological level involves thyroid hormone transporters and nuclear receptors. T3 entry into cells depends on specific transporters, and during critical illness their expression may vary in an organ-specific manner, modifying actual intracellular hormone exposure. Downstream, thyroid receptor signalling may be remodelled by inflammation and cellular stress, with changes in receptor affinity, availability of transcriptional cofactors and gene responses. This explains why simply increasing serum hormone levels through treatment may not result in uniform recovery of tissue function and why NTIS should not be interpreted solely as a “quantitative deficiency” of circulating hormones.
Finally, the balance between an adaptive and a maladaptive response depends on the clinical context. During the initial phase, reduced thyroid hormone signalling may decrease energy expenditure and proteolysis, integrating with the organism’s “stress and fasting” programme. During prolonged phases, particularly in patients with extended hospital stays and persistent catabolism, central suppression of the axis could contribute to sarcopenia, impaired tissue repair and frailty. However, demonstrating that pharmacological correction of this condition improves clinical outcomes requires robust evidence and cannot be inferred from the biological rationale alone.
Low T3 syndrome does not have a specific clinical presentation in itself because it develops in the context of a systemic illness that dominates the symptoms and signs. Its clinical presentation is therefore not that of “classic hypothyroidism”, but that of the underlying condition, with a potential contribution from thyroid hormone remodelling to metabolism, thermoregulation and cardiovascular function that is often difficult to isolate. In many situations, the patient appears clinically euthyroid in the traditional sense, despite laboratory results consistent with reduced T3 availability.
The symptoms reported in the medical history are typically those of the acute event or exacerbated chronic disease, including fever or hypothermia, dyspnoea, pain, marked asthenia, reduced food intake, nausea and gastrointestinal disturbances, confusion or somnolence, and signs of shock in the most severe cases. Features that resemble hypothyroidism, such as relative bradycardia, reduced intestinal motility or cold intolerance, may occur, but they are non-specific and are often explained by medications, sedation, multiple organ dysfunction and immobility.
On physical examination, the clinical picture is dominated by vital signs and the manifestations of critical illness. In sepsis and shock, haemodynamic instability and perfusion abnormalities predominate, whereas in advanced heart failure or severe respiratory syndromes, signs of congestion and hypoxia are more prominent. The presence of thyroid enlargement, ophthalmopathy or skin findings typical of chronic thyroid dysfunction suggests a concomitant primary thyroid disorder, but these findings are absent in most patients with NTIS.
Laboratory testing may show reduced FT3 and total T3, with a non-elevated TSH. In more severe or prolonged forms, FT4 may also decrease. An increase in rT3, when measured, supports the diagnosis of NTIS, but it is not always available in clinical practice and is unnecessary in most diagnostic pathways. Interpretation must also account for changes in binding proteins, albumin, hepatic and renal function and pharmacological interference, because “thyroid biochemistry” during critical illness represents a highly disrupted system.
It is important to emphasise that the clinical profile of severe hypothyroidism with multiple organ impairment, as occurs in myxoedema coma, represents a distinct entity. In that condition, the medical history, hypoventilation, marked hypothermia, bradycardia, hyponatraemia and findings compatible with advanced primary hypothyroidism are generally associated with a markedly elevated TSH, a scenario that does not correspond to the typical low T3 syndrome of non-thyroidal critical illness.
Low T3 syndrome should be suspected when a patient with a significant systemic illness develops thyroid function test abnormalities that do not follow the expected patterns of primary thyroid diseases. In practice, suspicion is strong when low T3 with normal or low TSH is observed during sepsis, shock, trauma, major surgery, advanced heart failure or another critical condition, particularly when there is no known history of thyroid dysfunction and physical examination does not suggest a primary thyroid disorder.
Suspicion should be particularly high in patients admitted to critical care areas or wards managing highly complex conditions, because in these settings the probability that the abnormality represents NTIS is high, and its automatic interpretation as hypothyroidism may lead to unnecessary treatment. The presence of malnutrition, energy deficit, a marked inflammatory response and the use of medications that modulate the thyroid axis further strengthen this hypothesis.
The assessment must also consider the possibility of previously undiagnosed hypothyroidism or a concomitant thyroid disorder. Useful clues include a history of thyroid disease, ongoing replacement therapy, development of goitre, known thyroid antibody positivity, previous thyroid surgery, cervical radiotherapy or a family history of thyroid disease. In these cases, the critical event may “mask” or modify the biochemical presentation, and the evaluation must integrate the clinical history with cautious interpretation of test results.
Finally, the syndrome should also be considered when an abnormal thyroid panel has been obtained as a “screening” test in patients admitted for non-endocrine conditions. In the absence of specific signs of thyroid dysfunction and in the presence of an intercurrent illness, NTIS is often more likely than a newly developed thyroid disorder. In most cases, the safest strategy is to focus on the underlying condition and plan reassessment after the acute phase has resolved.
The diagnosis of low T3 syndrome is essentially clinical and laboratory-based and requires thyroid function tests to be interpreted within the context of the systemic illness. The first step is to recognise the typical pattern: reduced T3 with a non-elevated TSH, often with normal FT4 in milder forms and reduced FT4 in more severe or prolonged forms. Particularly in an acutely or critically ill patient, this pattern is more consistent with NTIS than with primary hypothyroidism, in which TSH tends to rise proportionally to the reduction in FT4.
In practice, the most commonly available tests are TSH and FT4, sometimes supplemented by FT3. Measuring FT3 becomes more useful when the clinical question concerns the presence of NTIS in a patient with severe systemic illness, because reduced FT3 may make the pattern more evident. Measurement of rT3 may provide additional support for NTIS, but it is unnecessary in most cases and is not universally available. Its interpretation also requires expertise and awareness of analytical variables.
A crucial point is to avoid overinterpreting results obtained under conditions that alter protein binding and analytical accuracy. Hypoproteinaemia, hepatic dysfunction, renal failure, heparin use, changes in albumin and lipid concentrations and differences between immunometric assays may influence FT4 and FT3 measurements. In selected settings, when the result is clinically decisive, confirmation using more robust methods for free hormone measurement or repeat testing after greater clinical stability may be useful.
The main differential diagnoses include central hypothyroidism and primary hypothyroidism. In central hypothyroidism, TSH is low or inappropriately normal with reduced FT4, a pattern that may resemble NTIS in severe and prolonged cases. Differentiation requires a detailed medical history, assessment of other pituitary axes, evaluation for signs of hypothalamic-pituitary disease and, when indicated, hypothalamic-pituitary imaging. In primary hypothyroidism, the main distinguishing feature is often a significantly elevated TSH associated with reduced FT4 and a compatible clinical history.
A pragmatic hospital-based approach is to consider low T3 syndrome the most likely diagnosis when thyroid function test abnormalities arise during a major acute illness, in the absence of a thyroid history, with a non-elevated TSH and a clinical picture dominated by the systemic condition. In these cases, the most useful investigation is often reassessment of thyroid function tests after resolution or stabilisation of the acute event, because many abnormalities resolve spontaneously, whereas persistence of an abnormal pattern after recovery more strongly suggests an underlying thyroid disorder.
A clinically useful classification distinguishes low T3 syndrome according to the extent of the abnormality and the phase of the illness. In mild forms, an isolated reduction in T3 with FT4 within the reference range and normal TSH is typical. This pattern develops early and may be interpreted as part of a metabolic response to stress and energy deficit. In many situations, it is transient and normalises as the illness resolves.
In moderate forms, in addition to reduced T3, an increase in rT3 is more frequently observed, together with a tendency for TSH to fall within the lower part of the reference range or to decrease, depending on medication use and clinical severity. At this stage, the peripheral component related to hormone conversion and inactivation remains predominant, but central signals and changes in secretion are already involved.
In severe and especially prolonged forms, FT4 may also decrease, with low or inappropriately normal TSH. This pattern is common in patients with lengthy hospital stays, persistent catabolism and prolonged intensive support, and reflects more marked suppression of the axis and reduced thyroid hormone production, in addition to persistent peripheral remodelling. In this setting, some authors have proposed a potentially maladaptive component and have investigated experimental strategies to reactivate the axis, but translating these concepts into standard treatment indications requires definitive clinical evidence.
A further distinction concerns the presence or absence of a concomitant thyroid disorder. In patients with known hypothyroidism receiving replacement therapy, critical illness may alter absorption, conversion and tissue availability, making test results more difficult to interpret. Conversely, in patients with hyperthyroidism or thyrotoxicosis, NTIS may transiently attenuate some abnormalities, creating “hybrid” profiles. In these cases, classification and management must be guided by the medical history and clinical trajectory rather than by a single laboratory panel.
Treatment of low T3 syndrome focuses on managing the underlying condition and optimising the factors responsible for thyroid hormone remodelling, rather than pharmacologically correcting hormone values. In most clinical settings, the available evidence does not support routine use of levothyroxine (T4) or liothyronine (T3) to improve hard clinical outcomes such as mortality or functional recovery. Many reviews emphasise that randomised trials have been small, heterogeneous and frequently inconclusive. The standard approach is therefore to avoid thyroid hormone replacement in NTIS unless a documented thyroid disorder requiring specific treatment is present.
The practical priority is to promptly recognise and treat infections, shock, respiratory failure, heart failure, renal and hepatic failure, and to correct metabolic and nutritional imbalances. Management of nutrition in intensive care, the supportive strategy and reduction of unnecessary pharmacological interference may also influence the course of thyroid abnormalities. In many patients, thyroid function tests normalise in parallel with clinical improvement without direct endocrine intervention.
There are, however, situations in which endocrinological assessment is essential. If concomitant primary or central hypothyroidism is clinically suspected, replacement therapy may be indicated, but it must be initiated with extreme caution in critically ill patients, taking into account haemodynamic instability, arrhythmic risk and medication interactions. In patients with heart disease, in particular, T3 administration may have chronotropic and inotropic effects and is not a neutral intervention. Furthermore, before starting thyroid hormone replacement in a severely ill patient, possible adrenal insufficiency must be excluded or treated, because increased hormone metabolism and energy demand may worsen clinical stability.
Research has explored approaches intended to reactivate the hypothalamic-pituitary-thyroid axis in prolonged forms, including stimulation with hypothalamic releasing factors combined with other anabolic strategies. These interventions remain experimental and are not part of standard practice. In routine clinical management, the objective remains to avoid unnecessary treatments, protect the patient from iatrogenic harm and ensure endocrinological reassessment after clinical stabilisation.
Follow-up of low T3 syndrome primarily consists of follow-up of the underlying disease, accompanied by a reasoned strategy for monitoring thyroid function tests. In patients admitted with acute conditions, frequent repetition of thyroid hormone measurements during the unstable phase should often be avoided unless there is a specific suspicion of primary or central thyroid disease or another defined clinical need. “Serial” repetition of tests without a clinical question may lead to unnecessary interventions.
After the acute phase has resolved or clinical stability has been achieved, reassessment of TSH and FT4 is useful, with FT3 added when appropriate for the clinical context. The optimal timing depends on the severity and duration of the illness, but the clinical principle is to allow sufficient time for the axis and tissue metabolism to realign. Normalisation of test results supports the functional and reversible nature of the condition. Persistent elevation of TSH with reduced FT4 suggests primary hypothyroidism, whereas persistently reduced FT4 with low or inappropriately normal TSH requires assessment for central hypothyroidism.
In patients with advanced chronic disease, such as end-stage heart or kidney failure, severe liver disease or advanced malignancy, the syndrome may be persistent or fluctuate over time. In these cases, monitoring should aim to distinguish a stable NTIS profile from a newly developed thyroid disorder, avoiding automatic interpretations. The medical history, physical examination and clinical trajectory remain central, because an isolated laboratory result may be misleading.
If the patient was already receiving thyroid hormone replacement before the acute event, follow-up should include assessment of adherence, absorption and medication interactions, with gradual adjustments based on clinical parameters and tests performed under relatively stable conditions. In intensive care or during continuous enteral nutrition, for example, levothyroxine absorption may be reduced and may require temporary adjustments that must subsequently be reassessed after return to usual conditions.
The prognosis of low T3 syndrome is closely linked to the prognosis of the underlying condition. In many clinical cohorts, lower T3 levels and the presence of reduced T4 are associated with more severe illness and worse outcomes. In this sense, NTIS may be regarded as an integrated marker of disease severity and systemic stress. However, this association does not demonstrate causality and does not automatically imply that pharmacological correction of serum hormone levels improves outcomes.
From a management perspective, the main “complication” is diagnostic and therapeutic error. Interpreting NTIS as primary hypothyroidism and initiating unnecessary treatment may expose the patient to iatrogenic harm, particularly in the presence of cardiovascular instability, arrhythmic risk and multiple organ dysfunction. Similarly, labelling a patient as “hypothyroid” during a critical phase may generate inappropriate follow-up and subsequent interventions based on a transient abnormality.
Another critical issue is failure to identify a genuine thyroid disorder or central hypothyroidism masked by critical illness. In this case, the “complication” is the opposite: attributing all abnormalities to NTIS and failing to recognise an endocrine condition that requires treatment. To reduce this risk, the safest approach is to remain alert to strongly suggestive clinical features, the patient’s medical history and persistence of abnormalities after the acute phase.
Overall, low T3 syndrome is a condition with major interpretative implications rather than an autonomous endocrine disease. Optimal management, including from a prognostic perspective, consists of treating the underlying cause, avoiding thyroid interventions unsupported by evidence and arranging targeted endocrinological reassessment after the patient has passed the phase of greatest instability.